Even before Scott Gottlieb took the top job at the Food and Drug Administration, there were signs his tenure would be different.

For one, he had ties to the pharmaceutical industry — he served on company boards, he worked in venture capital firms that invested in health care companies, and he was a resident fellow at the American Enterprise Institute, a conservative think tank that supports deregulation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • What disappointed me most about Gottlieb was his failure to end the FDA ban on genetically modified salmon. After a twenty seven year investigation, FDA finally agreed in Nov 2015 that it was safe to eat and safe for the environment, but immediately after finding it safe, FDA issued a ban on raising it and selling it in the United States until FDA could issue a rule about how it should be labeled at point of sale. Then FDA also said that it had no authority to issue such a labeling rule, but continued the ban. Finally, after Congress passed a law that required all GMO foods to be labeled in accordance to a rule from USDA, that USDA rule was issued late last year, but FDA still won’t lift its ban for the tenuous reason that the labeling rule wouldn’t count because it didn’t come from FDA. This makes catch-22 look like child’s play.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy